背景:随着年龄的增长,他们可能发展为阿尔茨海默病(AD),其特点是言语困难,记忆丧失,和其他与神经功能有关的问题。环黄芪醇是黄芪的活性成分,已被用于治疗炎症,老化,心脏病,和癌症。
目的:本研究旨在探讨环黄芪醇对实验性AD大鼠的潜在治疗益处。此外,还通过测量参与氧化应激的Nrf2和HO-1来评估潜在的分子机制,NFκB和TNF-α,参与炎症,和BCL2,BAX,和caspase-3,参与细胞凋亡。
方法:Sprague-Dawley大鼠每天腹腔注射70mg/kg氯化铝,连续6周诱导AD。AD诱导后,大鼠每天口服25mg/kg环黄芪醇,连续三周。海马切片用苏木精/伊红和抗胱天蛋白酶-3抗体染色。Nrf2,HO-1,NFκB,TNF-α,BCL2,BAX,分析了样品中caspase-3基因的表达和蛋白质水平。
结果:环黄芪醇可显著改善大鼠的行为学测试表现。它还加强了海马的组织。环黄芪醇显著改善大鼠行为表现和海马结构。它导致NFκB的表达明显下降,TNF-α,巴克斯,和caspase-3,这与BCL2,Nrf2和HO-1的表达增加有关。
结论:环黄芪醇可改善AD大鼠海马结构。它增强了行为测试的结果,降低了大脑中AChE的浓度,并发挥抗氧化和抗炎作用。还注意到抗凋亡作用,导致认知功能的显著改善,记忆,和接受治疗的大鼠的行为。
BACKGROUND: As individuals age, they may develop Alzheimer\'s disease (AD), which is characterized by difficulties in speech, memory loss, and other issues related to neural function. Cycloastragenol is an active ingredient of Astragalus trojanus and has been used to treat inflammation, aging, heart disease, and cancer.
OBJECTIVE: This study aimed to explore the potential therapeutic benefits of cycloastragenol in rats with experimentally induced AD. Moreover, the underlying molecular mechanisms were also evaluated by measuring Nrf2 and HO-1, which are involved in oxidative stress, NFκB and TNF-α, which are involved in inflammation, and BCL2, BAX, and caspase-3, which are involved in apoptosis.
METHODS: Sprague-Dawley rats were given 70 mg/kg of aluminum chloride intraperitoneally daily for six weeks to induce AD. Following AD induction, the rats were given 25 mg/kg of cycloastragenol daily by oral gavage for three weeks. Hippocampal sections were stained with hematoxylin/ eosin and with anti-caspase-3 antibodies. The Nrf2, HO-1, NFκB, TNF-α, BCL2, BAX, and caspase-3 gene expressions and protein levels in the samples were analyzed.
RESULTS: Cycloastragenol significantly improved rats\' behavioral test performance. It also strengthened the organization of the hippocampus. Cycloastragenol significantly improved behavioral performance and improved hippocampal structure in rats. It caused a marked decrease in the expression of NFκB, TNF-α, BAX, and caspase-3, which was associated with an increase in the expression of BCL2, Nrf2, and HO-1.
CONCLUSIONS: Cycloastragenol improved the structure of the hippocampus in rats with AD. It enhanced the outcomes of behavioral tests, decreased the concentration of AChE in the brain, and exerted antioxidant and anti-inflammatory effects. Antiapoptotic effects were also noted, leading to significant improvements in cognitive function, memory, and behavior in treated rats.